Researchers Discover How Tumor Suppressor Gene Works
Posted on: Sunday, 10 July 2005, 18:35 CDT
MINNEAPOLIS / ST. PAUL - A team of University of Minnesota researchers has discovered how a gene that suppresses the development of melanoma and other human cancers works. The study points the way to treatments based on the function of the gene. The researchers, led by Zigang Dong, director of the university's Hormel Institute in Austin, Minn., have applied for a patent on one such treatment. The work will be published online July 10 in the journal Nature Structural & Molecular Biology.
A critical event in the development of melanoma and other human cancers is the inactivation of a gene known as "p16." Normally, p16 keeps cells from growing rapidly, a condition that sometimes leads to tumor formation. Working with mouse epidermis and cultured human melanoma and nonmelanoma cancer cells, the team found that p16 inactivates key enzymes -- called JNK 1 and JNK 2 -- in the process. The enzymes are normally activated by exposure to ultraviolet light. By shutting down the enzymes, p16 keeps them from activating a huge complex of proteins, which, when active, attaches to chromosomes and turns on many genes that promote cell growth.
The p16 gene works by producing a protein that attaches to the enzymes, preventing them from performing their function. When the researchers added the p16 protein to colonies of cancer cells in culture, it diminished the size of many colonies, wiping out some of them. It also decreased the total number of cancer cells.
The researchers have designed a very small protein that mimics the action of the natural p16 protein.
"We hope this [small protein] will have anti-cancer activity," said Dong. "We are testing it now." A patent application on the protein has been filed. Dong said he hopes to see clinical trials of this or similar treatments begin in a few years.
On the World Wide Web:
Related Articles
- Integrated Stem Cell-Gene Therapy Approach Cures Human Genetic Disease In Vitro
- Cancer Enzymes Found in Zebrafish Study
- New Data on MAGE-A3 Cancer Immunotherapy Support Potential Novel Options of Treating Non-Small Cell Lung Cancer and Melanoma
- NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the GTCbio Cancer Drugs Research & Development Conference
- RNA May Play Larger Role in Cell's Gene Activity, Stanford Researchers Find
- OHSU Cancer Institute Researcher Identifies Protein Marker for Prostate Cancer Survival
- View Scientific Rationale for Novel Therapeutics in Lung Cancer, And the Results of Clinical Trials to Date Inside 'Triple Analysis: Non Small Cell Lung Cancer, Protein Kinase Inhibitors & Anti-Angiogenic Agents'
- Talabostat Phase 2 Non-Small Cell Lung Cancer Trial Featured at the 14th International Conference on Gene Therapy of Cancer
- Missing Protein May Hold Lung Cancer Key -Research
- New Targets for Detection and Treatment of Small Cell Lung Cancer*
 |
 |
User Comments (0)
RSS Feeds